Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 20/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.76 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17222968 | 1.00 | RBP4 (1.00) | RBP4CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL30949139 | 0.86 | RBP4 (1.00) | RBP4CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL17222935 | 0.86 | RBP4 (0.76) | RBP4CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL17229647 | 0.86 | RBP4 (0.76) | RBP4CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL17505216 | 0.86 | RBP4 (1.00) | RBP4CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL29813210 | 0.86 | RBP4 (0.76) | RBP4CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL17222857 | 0.86 | RBP4 (1.00) | RBP4CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL17222997 | 0.85 | RBP4 (1.00) | RBP4CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL29813105 | 0.85 | RBP4 (1.00) | RBP4CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL17222947 | 0.82 | RBP4 (1.00) | RBP4CYP3A4CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4691465-A2 | SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | The Trustees of Columbia University in the City of New York (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4036094-B1 | SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | UNIV COLUMBIA (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20240398780-A1 | METHODS OF TREATING RBP4 RELATED DISEASES WITH TRIAZOLOPYRIDINES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2024-12-05 | — | — | US | disclosed |
| US-12016853-B2 | Methods of treating RBP4 related diseases with triazolopyridines | BELITE BIO, INC (KY) | 2024-06-25 | — | — | US | disclosed |
| US-20230312585-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-10-05 | — | — | US | disclosed |
| CN-111393434-B | Substituted 4-phenylpiperidines, their preparation and use | 哥伦比亚大学董事会 | 2022-11-04 | — | — | CN | disclosed |
| EP-4036094-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | The Trustees of Columbia University in the City of New York (US) | 2022-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312585-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | HRH4, HRH3, HRH2 | RBP4 1884/4885CYP3A4 117/4885CYP2D6 317/4885 |
| US-12016853-B2 | Methods of treating RBP4 related diseases with triazolopyridines | RBP4, RBP1, RBBP4 | RBP4 1/4885CYP3A4 3534/4885CYP2D6 4850/4885 |
| US-20240398780-A1 | METHODS OF TREATING RBP4 RELATED DISEASES WITH TRIAZOLOPYRIDINES | RBP4, RBP1, RBBP4 | RBP4 1/4885CYP3A4 3534/4885CYP2D6 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.